Long-term follow-up of the Hemodialysis Infection Prevention with Polysporin Ointment (HIPPO) study: A quality improvement report

American Journal of Kidney Diseases

Volumn 57, Issue 3, 2011, Pages 432-441

  Battistella, Marisa ^a,b   Bhola, Cynthia ^a   Lok, Charmaine E ^a,b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bacteremia; catheter; hemodialysis; infection; prevention

Indexed keywords

POLYSPORIN;

ADULT; AGED; ARTICLE; BACTEREMIA; CATHETER INFECTION; CENTRAL VENOUS CATHETER; FEMALE; GRAM POSITIVE BACTERIUM; HEALTH CARE POLICY; HEMODIALYSIS PATIENT; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; TOTAL QUALITY MANAGEMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACITRACIN; CATHETER-RELATED INFECTIONS; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; GRAMICIDIN; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OINTMENTS; ONTARIO; POLYMYXIN B; PROSPECTIVE STUDIES; QUALITY IMPROVEMENT; RENAL DIALYSIS; TIME FACTORS; YOUNG ADULT;

EID: 79951808929     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2010.10.009     Document Type: Article

References (42)

1. Mendelssohn DC, Ethier J, Elder SJ, Saran R, Port FK, Pisoni RL. Haemodialysis vascular access problems in Canada: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS II). Nephrol Dial Transplant. 2005;21:721-728.
2. National Kidney Foundation. KDOQI Clinical Practice Guidelines for Vascular Access. Am J Kidney Dis. 2006;48(suppl 1):S176-247.
3. Jindal K, Chan CT, Deziel C, et al. Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. Chapter 4: vascular access. J Am Soc Nephrol. 2006;17(suppl 1):S16-23.
4. Saad TF. Central venous dialysis catheters: catheter-associated infection. Semin Dial. 2001;14(6):446-451. (Pubitemid 33720890)
5. Hakim RM, Himmelfarb J. Hemodialysis access failure: a call to action-revisited. Kidney Int. 2009;76:1040-1048.
6. Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK. Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int. 2001;60(4):1443-1451. (Pubitemid 32960038)
7. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol. 1998;9(5):869-876.
8. Pastan S, Soucie JM, McClellan WM. Vascular access and increased risk of death among hemodialysis patients. Kidney Int. 2002;62(2):620-626. (Pubitemid 34779776)
9. Taylor G, Gravel D, Johnston L, et al. Prospective surveillance for primary bloodstream infections occurring in Canadian hemodialysis units. Infect Control Hosp Epidemiol. 2002;23(12):716-720. (Pubitemid 36020207)
10. Thomson PC, Stirling CM, Geddes CC, Morris ST, Mactier RA. Vascular access in haemodialysis patients: a modifiable risk factor for bacteraemia and death. QJM. 2007;100(7):415-422. (Pubitemid 47062893)
11. Ishani A, Collins AJ, Herzog CA, Foley RN. Septicemia, access and cardiovascular disease in dialysis patients: the USRDS Wave 2 study. Kidney Int. 2005;68(1):311-318. (Pubitemid 43181390)
12. Engemann JJ, Friedman JY, Reed SD, et al. Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. Infect Control Hosp Epidemiol. 2005;26(6):534-539. (Pubitemid 40896143)
13. Marr KA, Kong L, Fowler VG, et al. Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients. Kidney Int. 1998;54(5):1684-1689. (Pubitemid 28502911)
14. Maraj S, Jacobs LE, Kung SC, et al. Epidemiology and outcome of infective endocarditis in hemodialysis patients. Am J Med Sci. 2002;324(5):254-260. (Pubitemid 35278770)
15. US Renal Data System. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2009.
16. Ramanathan V, Chiu EJ, Thomas JT, Khan A, Dolson GM, Darouiche RO. Healthcare costs associated with hemodialysis catheter-related infections: a single-center experience. Infect Control Hosp Epidemiol. 2007;28(5):606-609. (Pubitemid 46814554)
17. Mokrzycki MH, Zhang M, Cohen H, Golestaneh L, Laut JM, Rosenberg SO. Tunnelled haemodialysis catheter bacteraemia: risk factors for bacteraemia recurrence, infectious complications and mortality. Nephrol Dial Transplant. 2006;21:1024-1031.
18. Tanriover B, Carlton D, Saddekni S, et al. Bacteremia associated with tunneled dialysis catheters: comparison of two treatment strategies. Kidney Int. 2000;57(5):2151-2155. (Pubitemid 30252310)
19. Lok CE, Stanley KE, Hux JE, Richardson R, Tobe SW, Conly J. Hemodialysis infection prevention with Polysporin ointment. J Am Soc Nephrol. 2003;14(1):169-179. (Pubitemid 36026307)
20. Lok CE, Appleton D, Bhola C, Khoo B, Richardson RM. Trisodium citrate 4% - an alternative to heparin capping of haemodialysis catheters. Nephrol Dial Transplant. 2007;22(2):477-483. (Pubitemid 46189892)
21. Division of Nosocomial and Occupationl Infectious Diseases, Bureau of Infectious Diseases, Laboratory Centre for Disease Control, Health Canada. Preventing infections associated with indwelling intravascular access devices. Can Commun Dis Rep. 1997;23(suppl 8):i-iii, 1-32; i-iv, 31-16.
22. Manian FA. IDSA guidelines for the diagnosis and management of intravascular catheter-related bloodstream infection. Clin Infect Dis. 2009;49(11):1770-1771; author reply 1771-1772.
23. Clinical and Laboratory Standards Institute. Performance Standard for Antimicrobial Susceptibility Testing. Document M100-S15. Wayne, PA: Clinical and Laboratory Standards Institute; 2005.
24. NCCLS. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, Approved Standard. Wayne, PA: National Committee for Clinical Laboratory Standards; 2003.
25. Moist LM, Trpeski L, Na Y, Lok CE. Increased hemodialysis catheter use in Canada and associated mortality risk: data from the Canadian Organ Replacement Registry 2001-2004. Clin J Am Soc Nephrol. 2008;3(6):1726-1732.
26. Collins AJ, Foley RN, Gilbertson DT, Chen SC. The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clin J Am Soc Nephrol. 2009;4(suppl 1):S5-11.
27. Schaubel DE, Fenton SSA. Trends in mortality rates on hemodialysis in Canada, 1981-1997. Kidney Int Suppl. 2000;57:S66-S73.
28. Lee T, Barker J, Allon M. Tunneled catheters in hemodialysis patients: reasons and subsequent outcomes. Am J Kidney Dis. 2005;46(3):501-508. (Pubitemid 41208186)
29. McIntyre CW, Hulme LJ, Taal M, Fluck RJ. Locking of tunneled hemodialysis catheters with gentamicin and heparin. Kidney Int. 2004;66(2):801-805. (Pubitemid 38986971)
30. Weijmer MC, van den Dorpel MA, Van de Ven PJ, et al; CITRATE Study Group. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J Am Soc Nephrol. 2005;16(9):2769-2777.
31. Dogra GK, Herson H, Hutchison B, et al. Prevention of tunneled hemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: a randomized controlled study. J Am Soc Nephrol. 2002;13(8):2133-2139. (Pubitemid 34790791)
32. Saad TF. Bacteremia associated with tunneled, cuffed hemodialysis catheters. Am J Kidney Dis. 1999;34(6):1114-1124.
33. Mokrzycki MH, Zhang M, Golestaneh L, Laut J, Rosenberg SO. An interventional controlled trial comparing 2 management models for the treatment of tunneled cuffed catheter bacteremia: a collaborative team model versus usual physician-managed care. Am J Kidney Dis. 2006;48(4):587-595. (Pubitemid 44402836)
34. Ashby DR, Power A, Singh S, et al. Bacteremia associated with tunneled hemodialysis catheters: outcome after attempted salvage. Clin J Am Soc Nephrol. 2009;4(10):1601-1605.
35. Jones RN, Li Q, Kohut B, Biedenbach DJ, Bell J, Turnidge JD. Contemporary antimicrobial activity of triple antibiotic ointment: a multiphased study of recent clinical isolates in the United States and Australia. Diagn Microbiol Infect Dis. 2006;54(1):63-71. (Pubitemid 41815190)
36. Oliveira L, Graham J, Lok C, MacFarlane S, Zimmerman D. Risk factors for yeast superinfection in the treatment of suspected exit site infections: a case-control study. J Vasc Access. 2008;9(1):35-38. (Pubitemid 351618713)
37. Tokars JI. Description of a new surveillance system for bloodstream and vascular access infections in outpatient hemodialysis centers. Semin Dial. 2000;13(2):97-100.
38. Tokars JI, Miller ER, Stein G. New national surveillance system for hemodialysis-associated infections: initial results. Am J Infect Control. 2002;30(5):288-295. (Pubitemid 34852414)
39. Johnson DW, van Eps C, Mudge DW, et al. Randomized, controlled trial of topical exit-site application of honey (Medihoney) versus mupirocin for the prevention of catheter-associated infections in hemodialysis patients. J Am Soc Nephrol. 2005;16(5):1456-1462. (Pubitemid 41716531)
40. Grudzinski L, Quinan P, Kwok S, Pierratos A. Sodium citrate 4% locking solution for central venous dialysis catheters - an effective, more cost-efficient alternative to heparin. Nephrol Dial Transplant. 2007;22(2):471-476. (Pubitemid 46189891)
41. MacRae JM, Dojcinovic I, Djurdjev O, et al. Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS). Clin J Am Soc Nephrol. 2008;3:369-374.
42. Power A, Duncan N, Singh SK, et al. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single-center randomized controlled trial. Am J Kidney Dis. 2009;53:1034-1041.